XML 47 R40.htm IDEA: XBRL DOCUMENT
v3.21.4

CONTRACTUAL OBLIGATIONS (Narrative) (Details) |  |  |  | 1 Months Ended | 4 Months Ended | 5 Months Ended | 10 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | ---
Nov. 06, 2020 USD ($) | Oct. 09, 2020 USD ($) Shares | Jun. 05, 2020 Shares | Aug. 31, 2021 USD ($) | Apr. 23, 2021 CAD ($) shares | Apr. 23, 2021 USD ($) shares | Mar. 31, 2021 USD ($) | Jan. 31, 2021 Shares | Nov. 17, 2020 USD ($) Shares | May 26, 2020 CAD ($) | May 26, 2020 USD ($) | Sep. 30, 2019 CAD ($) | Apr. 28, 2021 Shares | Apr. 12, 2021 USD ($) | Sep. 30, 2021 CAD ($) | Sep. 30, 2021 USD ($) | Sep. 30, 2020 CAD ($)
Disclosure Of Contractual Obligation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  |  |  |  |  |  |  | $ 42,009 |  |  | $ 6,313,988 |  | $ 354,852
Option agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure Of Contractual Obligation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable option fees paid |  |  |  |  |  |  |  |  |  | $ 20,313 | $ 15,000 |  |  |  |  |  |
License agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure Of Contractual Obligation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Signing fee |  |  |  |  |  | $ 100,000 |  |  |  |  |  |  |  |  |  |  |
Option fees paid |  |  |  |  |  | $ 15,000 |  |  |  |  |  |  |  |  |  |  |
Signing fee, net of option fees paid |  |  |  |  | $ 105,502 |  |  |  |  |  |  |  |  |  |  |  |
Signing fee, shares issued | shares |  |  |  |  | 63,000 | 63,000 |  |  |  |  |  |  |  |  |  |  |
Percentage of royalties on net sales under $1 billion |  |  |  |  | 3.00% | 3.00% |  |  |  |  |  |  |  |  |  |  |
Percentage of royalties on net sales over $2 billion |  |  |  |  | 4.50% | 4.50% |  |  |  |  |  |  |  |  |  |  |
Description of sublicensee revenue of royalty payment accrues |  |  |  |  | royalty payments being credited toward the annual minimum for the license year in which the royalty payment accrues and 12% on all non-royalty revenue until the Company has raised $7.5 million and then 10% thereafter | royalty payments being credited toward the annual minimum for the license year in which the royalty payment accrues and 12% on all non-royalty revenue until the Company has raised $7.5 million and then 10% thereafter |  |  |  |  |  |  |  |  |  |  |
Annual minimum royalties - Years 1 and 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual minimum royalties - Year 3 |  |  |  |  | 5,000 |  |  |  |  |  |  |  |  |  |  |  |
Annual minimum royalties - Year 4 |  |  |  |  | 15,000 |  |  |  |  |  |  |  |  |  |  |  |
Annual minimum royalties - Year 5 |  |  |  |  | 35,000 |  |  |  |  |  |  |  |  |  |  |  |
Annual minimum royalties - Year 6 and thereafter |  |  |  |  | 50,000 |  |  |  |  |  |  |  |  |  |  |  |
Annual minimum royalties after first commercial sale |  |  |  |  | 250,000 |  |  |  |  |  |  |  |  |  |  |  |
Licensing agreement - prior to any sublicensing agreements, joint ventures or change of control [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure Of Contractual Obligation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments upon dosing first patient in Phase I trial |  |  |  |  | 10,000 |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments upon dosing first patient in the first Phase II trial |  |  |  |  | 50,000 |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments upon dosing first patient in the first Phase III trial |  |  |  |  | 250,000 |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments upon first commercial sale of each clinical indication |  |  |  |  | 2,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Licensing agreement - after any sublicensing agreements, joint ventures or change of control [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure Of Contractual Obligation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments upon dosing first patient in the first Phase II trial |  |  |  |  | 250,000 |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments upon dosing first patient in the first Phase III trial |  |  |  |  | 500,000 |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments upon first commercial sale of each clinical indication |  |  |  |  | $ 2,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Independent Consultant Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure Of Contractual Obligation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of options granted | Shares |  |  | 150,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of RSUs granted | Shares |  |  | 150,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Monthly fee authorized by board of directors |  |  |  | $ 25,000 |  |  | $ 15,000 |  |  |  |  |  |  |  |  |  |
Independent Contractor Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure Of Contractual Obligation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Monthly fee authorized by board of directors |  |  |  | $ 25,000 |  |  | $ 15,000 |  |  |  |  |  |  |  |  |  |
Scientific advisory board agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure Of Contractual Obligation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of options granted | Shares |  |  |  |  |  |  |  |  | 130,000 |  |  |  |  |  |  |  |
Number of options cancelled | Shares |  |  |  |  |  |  |  | 20,000 |  |  |  |  |  |  |  |  |
Scientific advisory board agreements [Member] | Bottom of range [member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure Of Contractual Obligation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Advisor hourly rate |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 150 |  |  |
Scientific advisory board agreements [Member] | Top of range [member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure Of Contractual Obligation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Advisor hourly rate |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 160 |  |  |
Consulting agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure Of Contractual Obligation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of options granted | Shares |  | 90,000 |  |  |  |  |  |  |  |  |  |  | 302,000 |  |  |  |
Monthly fee authorized by board of directors |  |  |  |  |  |  |  |  | $ 15,000 |  |  |  |  |  |  |  |
Advisor hourly rate |  | $ 130 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense | $ 66,764 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consulting agreements [Member] | Bottom of range [member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure Of Contractual Obligation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Advisor hourly rate |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 30 |
Consulting agreements [Member] | Top of range [member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure Of Contractual Obligation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Advisor hourly rate |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 600 |

X
- Definition Advisor hourly rate. + References No definition available. + Details
Name: | drug_AdvisorHourlyRate
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Information about description of sublicensee revenue of royalty payment accrues. + References No definition available. + Details
Name: | drug_DescriptionOfSublicenseeRevenueOfRoyaltyPaymentAccrues
Namespace Prefix: | drug_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | drug_DisclosureOfContractualObligationLineItems
Namespace Prefix: | drug_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition milestone payments upon dosing first patient in the first Phase II trial. + References No definition available. + Details
Name: | drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiTrial
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition milestone payments upon dosing first patient in the first Phase III trial. + References No definition available. + Details
Name: | drug_MilestonePaymentsUponDosingFirstPatientInFirstPhaseIiiTrial
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Information about milestone payments upon dosing first patient in Phase I trial. + References No definition available. + Details
Name: | drug_MilestonePaymentsUponDosingFirstPatientInPhaseITrial
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition milestone payments upon first commercial sale of clinical. + References No definition available. + Details
Name: | drug_MilestonePaymentsUponFirstCommercialSaleOfClinical
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Monthly Fee Authorized By Board of Directors. + References No definition available. + Details
Name: | drug_MonthlyFeeAuthorizedByBoardOfDirectors
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the amount of non-refundable option fees paid. + References No definition available. + Details
Name: | drug_NonRefundableOptionFeesPaid
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of option fees paid. + References No definition available. + Details
Name: | drug_OptionFeesPaid
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Information about percentage of royalties on net sales over 2 billion. + References No definition available. + Details
Name: | drug_PercentageOfRoyaltiesOnNetSalesOver2Billion
Namespace Prefix: | drug_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Information about percentage of royalties on net sales under $1 billion. + References No definition available. + Details
Name: | drug_PercentageOfRoyaltiesOnNetSalesUnder1Billion
Namespace Prefix: | drug_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of signing fee. + References No definition available. + Details
Name: | drug_SigningFee
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents amount paid towards signing fee net of option fees. + References No definition available. + Details
Name: | drug_SigningFeeNetOfOptionFeesPaid
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents signing fee, shares issued. + References No definition available. + Details
Name: | drug_SigningFeeSharesIssued
Namespace Prefix: | drug_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Information about total annual minimum royalties after first commercial sale. + References No definition available. + Details
Name: | drug_TotalAnnualMinimumRoyaltiesAfterFirstCommercialSale
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Information about total annual minimum royalties current years. + References No definition available. + Details
Name: | drug_TotalAnnualMinimumRoyaltiesCurrentYears
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Information about total annual minimum royalties current years 3. + References No definition available. + Details
Name: | drug_TotalAnnualMinimumRoyaltiesYear3
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Information about total annual minimum royalties years 4. + References No definition available. + Details
Name: | drug_TotalAnnualMinimumRoyaltiesYear4
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Information about total annual minimum royalties years 5. + References No definition available. + Details
Name: | drug_TotalAnnualMinimumRoyaltiesYear5
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Information about total annual minimum royalties year 6 and thereafter + References No definition available. + Details
Name: | drug_TotalAnnualMinimumRoyaltiesYear6AndThereafter
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2020-01-01 -Paragraph 47 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_47_b&doctype=Standard -URIDate 2020-01-01 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name IFRS -Number 2 -IssueDate 2020-01-01 -Paragraph 45 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of share options forfeited in a share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2020-01-01 -Paragraph 45 -Subparagraph b -Clause iii -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_b_iii&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of share options granted in a share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2020-01-01 -Paragraph 45 -Subparagraph b -Clause ii -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_b_ii&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of expenditure directly attributable to research or development activities, recognised in profit or loss. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 38 -IssueDate 2020-01-01 -Paragraph 126 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2020-en-r&anchor=para_126&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_ResearchAndDevelopmentExpense
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | drug_AgreementAxis=drug_OptionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | drug_AgreementAxis=drug_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | drug_AgreementAxis=drug_PriorToSublicensingAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | drug_AgreementAxis=drug_AfterSublicensingAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | drug_AgreementAxis=drug_IndependentConsultantAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | drug_AgreementAxis=drug_IndependentContractorAgreementToServeAsChiefScienceOfficerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | drug_AgreementAxis=drug_ScientificAdvisoryBoardAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | drug_AgreementAxis=drug_ConsultingAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |